Comparing two blood cancer treatment approaches for a rare lymphoma

This study is testing whether a treatment approach using venetoclax and rituximab works better than the standard approach using ibrutinib plus rituximab or zanubrutinib alone for people with Waldenström's macroglobulinemia, a rare blood cancer. Researchers want to know which combination helps more patients achieve a strong response to treatment and how well each treatment works over time.

Waldenström's macroglobulinemia is a rare cancer that has limited treatment options. Doctors want to find out whether venetoclax, a newer medication, could be a better choice than current standard treatments for patients who have never received treatment before.